Phaseline

Companies › Dompé Farmaceutici

Dompé Farmaceutici: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 3, 1 Phase 4, 1 Phase 2; Ophthalmology, Neurology, Immunology, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DFL24498–Phase 3Atopic Keratoconjunctivitis; Dry Eye Disease (DED)Dec 2026
Cenegermin
Neurotrophic tyrosine kinase receptor agonist
NTRK1, NTRK2, NTRK3Phase 3Non-Arteritic Anterior Ischemic Optic Neuropathy; Persistent Corneal Epithelial Defect; Dry EyeSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06947850CenegerminPhase 4Dry EyeOphthalmologySep 2025
NCT07503886DFL24498Phase 2Dry Eye Disease (DED)OphthalmologyDec 2026
NCT07395232DFL24498Phase 3Atopic KeratoconjunctivitisRespiratoryMar 2027
NCT07453888CenegerminPhase 3Non-Arteritic Anterior Ischemic Optic NeuropathyNeurologySep 2027
NCT07519902CenegerminPhase 3Persistent Corneal Epithelial DefectImmunologyDec 2027

Targets

NTRK1 (1) NTRK2 (1) NTRK3 (1)

Companies with the same targets

Xuanzhu Biopharmaceutical Nuvation Bio Roche Turning Point Therapeutics Bristol-Myers Squibb Teligene US Bayer VM Oncology BnH Research Shaanxi Micot Pharmaceutical Technology

Companies built like this

Andover Research Eye Institute Regenerative Ocular Immunobiologics SANGMYUNG innovation Cloudbreak Therapeutics YS Life Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.